DrugPatentWatch Database Preview
Drugs in Development Information for Tamibarotene
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Tamibarotene?
Tamibarotene is an investigational drug.
There have been 8 clinical trials for Tamibarotene.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2011.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Promyelocytic, Acute, and Paraparesis. The leading clinical trial sponsors are CytRx, Osaka City University, and Northwestern University.
There are three hundred and forty-three US patents protecting this investigational drug and two international patents.
Summary for Tamibarotene
| US Patents | 343 |
| International Patents | 2,983 |
| US Patent Applications | 597 |
| WIPO Patent Applications | 475 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2011-01-01) |
| Vendors | 79 |
Recent Clinical Trials for Tamibarotene
| Title | Sponsor | Phase |
|---|---|---|
| A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Syros Pharmaceuticals | Phase 2 |
| First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer | CytRx | Phase 2 |
| Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | St. Marianna University School of Medicine | Phase 2/Phase 3 |
Clinical Trial Summary for Tamibarotene
Top disease conditions for Tamibarotene
Top clinical trial sponsors for Tamibarotene
US Patents for Tamibarotene
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tamibarotene | Start Trial | Anticancer agent | Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP) | Start Trial |
| Tamibarotene | Start Trial | Pyrrolidinone derivatives as MetAP-2 inhibitors | Merck Patent GmbH (Darmstadt, DE) | Start Trial |
| Tamibarotene | Start Trial | .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof | Quadriga Biosciences, Inc. (Los Altos, CA) | Start Trial |
| Tamibarotene | Start Trial | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tamibarotene
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tamibarotene | Australia | 2015272560 | 2034-06-09 | Start Trial |
| Tamibarotene | Canada | 2951627 | 2034-06-09 | Start Trial |
| Tamibarotene | European Patent Office | 3153508 | 2034-06-09 | Start Trial |
| Tamibarotene | Japan | 6549115 | 2034-06-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
